Menostar Patch
NDC Package 50419-455-04
Package Information
Menostar (estradiol) patches is a medication a female hormone (estrogen). This formulation utilizes a patch delivery system. Marketed by Bayer Healthcare Pharmaceuticals Inc., this product is identified by NDC 50419-455 and is authorized under FDA application NDA020375.
Identification & Billing
- RxCUI: 476545 - estradiol 14 MCG/Day Weekly Transdermal System
- RxCUI: 476545 - 168 HR estradiol 0.000583 MG/HR Transdermal System
- RxCUI: 476545 - estradiol 0.000583 MG/HR Weekly Transdermal Patch
- RxCUI: 476545 - estradiol 14 MCG/Day Weekly Transdermal Patch
- RxCUI: 545276 - menostar 14 MCG/Day Weekly Transdermal System
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50419 - Bayer Healthcare Pharmaceuticals Inc.
- 50419-455 - Menostar
- 50419-455-04 - 4 PATCH in 1 CARTON / 7 d in 1 PATCH
- 50419-455 - Menostar
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50419-455-04 identifies a specific commercial package of 4 patch in 1 carton / 7 d in 1 patch of Menostar, a human prescription drug labeled by Bayer Healthcare Pharmaceuticals Inc.. This patch is formulated for transdermal use and contains estradiol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Pharmaceuticals Inc. on June 08, 2004. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is a female hormone (estrogen). It is used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.
How is this Bayer Healthcare Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50419045504. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.